Description

Thioguanine Tablets (40 mg)

Healthy Inc is a specialized global supplier and exporter of advanced hematological, oncology, and antineoplastic therapeutics. We provide ultra-high-purity, structurally validated Thioguanine Tablets (40 mg), manufactured in WHO–GMP certified, strictly dedicated negative-pressure hazardous oncology facilities. This “Purine Antagonist Antimetabolite” is a high-value, critical-care export to comprehensive cancer centers, hematology-oncology wards, and government health ministries in LATAM, the Middle East, Africa, and Southeast Asia, serving as a foundational, globally mandated intervention for the induction, consolidation, and maintenance of Acute Myeloid Leukemia (AML) and Acute Lymphoblastic Leukemia (ALL).

Product Overview

This formulation contains Thioguanine (also known as 6-Thioguanine or 6-TG), a highly potent synthetic purine analogue that physically sabotages the genetic replication machinery of rapidly dividing cancer cells.

The “DNA Terminator & Leukemia Eradicator” Specialist:

• Mechanism (The “False Building Block”): In order for leukemia cells to rapidly multiply, they must constantly synthesize new DNA and RNA using normal purine bases (like guanine). Thioguanine structurally mimics guanine. The cancer cells mistakenly absorb it and incorporate this “false nucleotide” directly into their DNA and RNA strands. Once incorporated, it physically prevents the DNA helix from replicating correctly, causing massive strand breaks and forcing the cancer cell to undergo apoptosis (programmed cell death).
• S-Phase Specificity: Because it requires the cell to be actively building DNA, Thioguanine is “cell-cycle phase-specific.” It aggressively hunts and destroys malignant leukocytes specifically during the S-phase (synthesis phase) of the cell cycle.
• The Hematology Standard: While newer targeted therapies exist, the sheer cytotoxic reliability of Thioguanine—often deployed in synergistic combination regimens with drugs like Cytarabine—makes it an indispensable, life-saving bedrock of global leukemia protocols.

Product Composition & Strength

We supply this product as a Precision-Blended Scored Tablet, packed in highly secure, moisture-resistant Alu-Alu blister strips or heavy-gauge HDPE bottles, engineered to maintain absolute stability and physical containment of the cytotoxic agent.

*Pack Sizes: Bottles of 25 / 100 Tablets or Specialized Alu-Alu Blisters (Optimized for strictly controlled oncology pharmacy dispensing).

Technical & Logistics Specifications

Critical data for Pharmaceutical Importers, Oncology Procurement Boards, and Hematology Networks.

Manufacturing Authority

Marketed and Distributed by Healthy Inc from WHO-GMP & ISO 9001:2015 certified oncology units.

• Hazardous Cytotoxic (OEB) Containment: Thioguanine is a highly potent, mutagenic, and teratogenic chemotherapy agent. Our manufacturing is executed within strictly isolated, completely dedicated Oncology blocks operating under severe negative pressure with multi-stage HEPA filtration. Powders are handled inside closed-loop barrier isolators (glove boxes) to guarantee absolute operator safety and zero cross-contamination with non-oncology drugs.
• Dose Uniformity for BSA Dosing: Because leukemia dosing is strictly calculated based on the patient’s exact Body Surface Area (BSA), any fluctuation in tablet strength can lead to fatal toxicity or treatment failure. Our facilities utilize advanced high-shear homogenizers and rigorous HPLC assay testing to guarantee flawless dose uniformity.

Therapeutic Indications (Human Use)

Indicated for the comprehensive management of severe hematological malignancies:

• Acute Myeloid Leukemia (AML): Indicated for remission induction, consolidation, and maintenance therapy in acute non-lymphocytic leukemias.
• Acute Lymphoblastic Leukemia (ALL): Used in specific multi-drug regimens for remission induction and maintenance.
• Chronic Myelogenous Leukemia (CML): Occasionally utilized in the treatment of the chronic phase or blast crisis of CML.

Dosage & Administration

Recommended Dosage (Strictly as per Board-Certified Hematologist/Oncologist):

• Body Surface Area Dosing: The dose is highly individualized. A common initiation dose is 2 mg/kg of body weight per day (or calculated strictly by BSA), administered as a single daily dose. If there is no clinical improvement and no leukocyte depression after 4 weeks, the dose may be cautiously increased.
• Administration (GASTRIC ABSORPTION RULE): It is generally recommended to take Thioguanine on an empty stomach (1 hour before or 2 hours after meals) to ensure maximum, consistent absorption, as food can significantly alter the bioavailability of purine analogues.
• Handling Precautions (HAZARD WARNING): Tablets should ideally be swallowed whole. If the scored tablet must be split to achieve an exact BSA dose, caregivers and healthcare providers MUST wear gloves and a mask. Pregnant women should never handle this medication.

Safety Warnings (CRITICAL Regulatory & Clinical Data):

• BLACK BOX EQUIVALENT (Severe Myelosuppression): Thioguanine causes profound, potentially fatal bone marrow suppression (leukopenia, thrombocytopenia, and anemia). Complete blood counts (CBC) must be monitored continuously (often weekly). The drug must be temporarily discontinued at the first sign of an abnormally large or rapid drop in leukocyte or platelet counts to prevent fatal sepsis or hemorrhage.
• Genetic Warning (TPMT & NUDT15 Deficiency): Patients with inherited genetic deficiencies in the Thiopurine S-methyltransferase (TPMT) or NUDT15 enzymes cannot metabolize Thioguanine properly. These patients will experience unusually severe, rapid, and catastrophic bone marrow failure. Genetic testing or enzyme phenotyping is highly recommended prior to initiating therapy.
• Hepatotoxicity & Veno-Occlusive Disease (VOD): Chronic maintenance therapy has been strongly associated with severe liver toxicity, specifically hepatic veno-occlusive disease (VOD), which can be fatal. Liver function tests (LFTs) must be monitored regularly.
• Teratogenicity: Catastrophic birth defects. Strictly contraindicated in pregnancy.

Global Export & Contract Manufacturing Services

Healthy Inc stands as a premier Pharmaceutical Exporter in India, dedicated to serving the needs of international Pharma Traders, Wholesalers, and Bulk Drug Distributors. As a verified Medicine Supplier in Mumbai, we offer flexible Third Party Manufacturing (Contract Manufacturing) services for Advanced Oncology and Hematology Formulations, allowing brands to launch high-quality generic medicines under their own label. Whether you are looking for a reliable Hospital Tender Supplier for government cancer programs in Africa or a B2B Pharma Marketplace partner for Southeast Asia, our logistics network ensures timely delivery. We actively support Pharmaceutical Drop Shipping models and bulk indenting, ensuring that every Specialty Medicine Wholesaler receives WHO-GMP certified products at competitive rates.